This activity was originally presented at the 2024 HOPA Annual Conference in Tampa, Florida.
Program Description
Recognizing the different phases of chronic myeloid leukemia (CML) is an important element of risk stratification and influences treatment selection. As the central goal of CML treatment is preventing progression to the accelerated or blast phase, oncology pharmacists must understand the expanding frontline treatment arsenal. This program will focus on BCR::ABL1-targeting tyrosine kinase inhibitors (TKIs) and present clinical considerations for oncology pharmacists involved in treatment selection and evaluating patient response to treatment. Panelists will present patient cases that examine strategies for managing TKI therapies for patients with advanced phase CML or inadequate treatment response. As these medications are oral and self-administered, practical counseling points to optimize adherence and appropriately manage adverse effects will also be discussed.
Target Audience: Oncology pharmacists
Type of Activity: Application
Release date: April 12, 2024
Expiration date: April 12, 2025
Learner level: Advanced
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Provide guidance for the assessment and management of chronic myeloid leukemia (CML) based on BCR::ABL1 mutation status
- Construct individualized treatment plans that address the unique needs of patients with CML, including the selection of appropriate drug therapies
- Employ guidance on medication adjustments, supportive care measures, and patient education to optimize adherence and overall treatment outcomes in patients with CML
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
